BE0002976570 analysis
Key facts
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Go deeper with bond data
Access the most important data for bonds including coupon rates, issue ratings, redemption data and more.